vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and TRANSCONTINENTAL REALTY INVESTORS INC (TCI). Click either name above to swap in a different company.
CytomX Therapeutics, Inc. is the larger business by last-quarter revenue ($18.7M vs $12.1M, roughly 1.5× TRANSCONTINENTAL REALTY INVESTORS INC). TRANSCONTINENTAL REALTY INVESTORS INC runs the higher net margin — 68.8% vs -0.8%, a 69.6% gap on every dollar of revenue. On growth, TRANSCONTINENTAL REALTY INVESTORS INC posted the faster year-over-year revenue change (2.3% vs -25.7%). Over the past eight quarters, TRANSCONTINENTAL REALTY INVESTORS INC's revenue compounded faster (0.7% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Transcontinental Realty Investors Inc. (TCI) is a U.S.-based real estate investment firm that owns, operates and develops a diversified portfolio of residential, commercial and mixed-use properties across core U.S. regional markets. It pursues long-term value growth via strategic property acquisitions, efficient asset management and tailored leasing solutions for individual and business tenants.
CTMX vs TCI — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $12.1M |
| Net Profit | $-154.0K | $8.3M |
| Gross Margin | — | — |
| Operating Margin | -6.9% | -28.9% |
| Net Margin | -0.8% | 68.8% |
| Revenue YoY | -25.7% | 2.3% |
| Net Profit YoY | 97.6% | 7577.8% |
| EPS (diluted) | — | $0.97 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $12.1M | ||
| Q3 25 | — | $12.8M | ||
| Q2 25 | $18.7M | $12.2M | ||
| Q1 25 | $50.9M | $12.0M | ||
| Q4 24 | $38.1M | $11.8M | ||
| Q3 24 | $33.4M | $11.6M | ||
| Q2 24 | $25.1M | $11.8M | ||
| Q1 24 | $41.5M | $11.9M |
| Q4 25 | — | $8.3M | ||
| Q3 25 | — | $724.0K | ||
| Q2 25 | $-154.0K | $169.0K | ||
| Q1 25 | $23.5M | $4.6M | ||
| Q4 24 | $18.9M | $108.0K | ||
| Q3 24 | $5.7M | $1.7M | ||
| Q2 24 | $-6.5M | $1.5M | ||
| Q1 24 | $13.8M | $2.5M |
| Q4 25 | — | -28.9% | ||
| Q3 25 | — | -10.9% | ||
| Q2 25 | -6.9% | -6.8% | ||
| Q1 25 | 44.4% | -5.3% | ||
| Q4 24 | 46.4% | -14.3% | ||
| Q3 24 | 12.3% | -14.4% | ||
| Q2 24 | -33.7% | -9.2% | ||
| Q1 24 | 28.1% | -11.2% |
| Q4 25 | — | 68.8% | ||
| Q3 25 | — | 5.6% | ||
| Q2 25 | -0.8% | 1.4% | ||
| Q1 25 | 46.2% | 38.5% | ||
| Q4 24 | 49.6% | 0.9% | ||
| Q3 24 | 17.2% | 14.7% | ||
| Q2 24 | -26.0% | 12.7% | ||
| Q1 24 | 33.3% | 21.4% |
| Q4 25 | — | $0.97 | ||
| Q3 25 | — | $0.08 | ||
| Q2 25 | — | $0.02 | ||
| Q1 25 | — | $0.53 | ||
| Q4 24 | — | $0.01 | ||
| Q3 24 | — | $0.20 | ||
| Q2 24 | — | $0.17 | ||
| Q1 24 | — | $0.30 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $89.0M |
| Total DebtLower is stronger | — | $210.8M |
| Stockholders' EquityBook value | $119.9M | $846.7M |
| Total Assets | $175.1M | $1.1B |
| Debt / EquityLower = less leverage | — | 0.25× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $89.0M | ||
| Q3 25 | — | $82.7M | ||
| Q2 25 | $49.0M | $73.5M | ||
| Q1 25 | $47.6M | $88.6M | ||
| Q4 24 | $38.1M | $99.7M | ||
| Q3 24 | $40.6M | $131.6M | ||
| Q2 24 | $43.2M | $127.5M | ||
| Q1 24 | $36.2M | $130.8M |
| Q4 25 | — | $210.8M | ||
| Q3 25 | — | $223.5M | ||
| Q2 25 | — | $212.4M | ||
| Q1 25 | — | $198.2M | ||
| Q4 24 | — | $181.9M | ||
| Q3 24 | — | $180.3M | ||
| Q2 24 | — | $177.4M | ||
| Q1 24 | — | $178.3M |
| Q4 25 | — | $846.7M | ||
| Q3 25 | — | $838.4M | ||
| Q2 25 | $119.9M | $837.7M | ||
| Q1 25 | $25.0M | $837.3M | ||
| Q4 24 | $-456.0K | $832.3M | ||
| Q3 24 | $-23.5M | $832.2M | ||
| Q2 24 | $-31.2M | $830.4M | ||
| Q1 24 | $-31.7M | $828.9M |
| Q4 25 | — | $1.1B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | $175.1M | $1.1B | ||
| Q1 25 | $98.5M | $1.1B | ||
| Q4 24 | $120.5M | $1.1B | ||
| Q3 24 | $139.0M | $1.1B | ||
| Q2 24 | $159.2M | $1.0B | ||
| Q1 24 | $184.7M | $1.0B |
| Q4 25 | — | 0.25× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 0.25× | ||
| Q1 25 | — | 0.24× | ||
| Q4 24 | — | 0.22× | ||
| Q3 24 | — | 0.22× | ||
| Q2 24 | — | 0.21× | ||
| Q1 24 | — | 0.22× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $-2.9M |
| Free Cash FlowOCF − Capex | $-15.8M | — |
| FCF MarginFCF / Revenue | -84.6% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | — | -0.35× |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-2.9M | ||
| Q3 25 | — | $8.2M | ||
| Q2 25 | $-15.8M | $-2.9M | ||
| Q1 25 | $-21.0M | $-7.4M | ||
| Q4 24 | $-19.9M | $1.3M | ||
| Q3 24 | $-20.7M | $13.7M | ||
| Q2 24 | $-19.5M | $-511.0K | ||
| Q1 24 | $-26.0M | $3.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-15.8M | — | ||
| Q1 25 | $-21.2M | — | ||
| Q4 24 | $-20.0M | — | ||
| Q3 24 | $-20.7M | — | ||
| Q2 24 | $-19.6M | — | ||
| Q1 24 | $-26.2M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -84.6% | — | ||
| Q1 25 | -41.6% | — | ||
| Q4 24 | -52.5% | — | ||
| Q3 24 | -62.1% | — | ||
| Q2 24 | -78.2% | — | ||
| Q1 24 | -63.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 0.3% | — |
| Q4 25 | — | -0.35× | ||
| Q3 25 | — | 11.28× | ||
| Q2 25 | — | -17.24× | ||
| Q1 25 | -0.89× | -1.61× | ||
| Q4 24 | -1.05× | 12.13× | ||
| Q3 24 | -3.61× | 8.03× | ||
| Q2 24 | — | -0.34× | ||
| Q1 24 | -1.89× | 1.52× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
TCI
Segment breakdown not available.
